BR112017023762A2 - formulações de depósito injetáveis - Google Patents

formulações de depósito injetáveis

Info

Publication number
BR112017023762A2
BR112017023762A2 BR112017023762-8A BR112017023762A BR112017023762A2 BR 112017023762 A2 BR112017023762 A2 BR 112017023762A2 BR 112017023762 A BR112017023762 A BR 112017023762A BR 112017023762 A2 BR112017023762 A2 BR 112017023762A2
Authority
BR
Brazil
Prior art keywords
injectable depot
depot formulations
formulations
compositions
treatment
Prior art date
Application number
BR112017023762-8A
Other languages
English (en)
Inventor
Ashton Paul
Original Assignee
Psivida Us, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psivida Us, Inc. filed Critical Psivida Us, Inc.
Publication of BR112017023762A2 publication Critical patent/BR112017023762A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

são divulgadas composições e métodos relacionados ao uso de inibidores da quinase no tratamento de degeneração macular e/ou oclusão de veia de retina.
BR112017023762-8A 2015-05-05 2016-05-05 formulações de depósito injetáveis BR112017023762A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562157257P 2015-05-05 2015-05-05
US62/157,257 2015-05-05
PCT/US2016/030912 WO2016179357A1 (en) 2015-05-05 2016-05-05 Injectable depot formulations

Publications (1)

Publication Number Publication Date
BR112017023762A2 true BR112017023762A2 (pt) 2018-07-31

Family

ID=57218334

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023762-8A BR112017023762A2 (pt) 2015-05-05 2016-05-05 formulações de depósito injetáveis

Country Status (10)

Country Link
US (1) US20160324836A1 (pt)
EP (1) EP3291812B1 (pt)
JP (1) JP2018520093A (pt)
CN (1) CN107530334A (pt)
AU (1) AU2016258001B2 (pt)
BR (1) BR112017023762A2 (pt)
CA (1) CA2984637A1 (pt)
MX (1) MX2017014084A (pt)
RU (1) RU2017137763A (pt)
WO (1) WO2016179357A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117398350A (zh) 2014-12-15 2024-01-16 约翰霍普金斯大学 舒尼替尼制剂及其在治疗青光眼中的使用方法
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
JP7217022B2 (ja) 2017-03-23 2023-02-02 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための薬物及び組成物
EP3621654A4 (en) 2017-05-10 2021-02-17 Graybug Vision, Inc. PROLONGED-RELEASE MICROPARTICLES AND SUSPENSIONS OF THESE INTENDED FOR MEDICAL THERAPY
WO2020250252A1 (en) * 2019-06-11 2020-12-17 Sifi S.P.A. Microemulsion compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
CN101890018B (zh) * 2009-05-22 2014-06-18 中国科学院化学研究所 一种酪氨酸蛋白激酶抑制剂及其制备方法
JP2014518232A (ja) * 2011-06-28 2014-07-28 バイエル・ヘルスケア・エルエルシー ソラフェニブを含有する眼科用局所医薬組成物
US9682141B2 (en) * 2011-11-11 2017-06-20 Intellikine Llc Combination of kinase inhibitors and uses thereof
KR20150000869A (ko) * 2011-12-14 2015-01-05 애브비 인코포레이티드 키나제 억제제를 함유하는 조성물

Also Published As

Publication number Publication date
CN107530334A (zh) 2018-01-02
EP3291812A1 (en) 2018-03-14
AU2016258001A1 (en) 2017-11-09
US20160324836A1 (en) 2016-11-10
AU2016258001B2 (en) 2020-06-04
JP2018520093A (ja) 2018-07-26
RU2017137763A (ru) 2019-06-05
MX2017014084A (es) 2018-06-20
EP3291812A4 (en) 2019-01-09
WO2016179357A1 (en) 2016-11-10
EP3291812B1 (en) 2021-09-01
RU2017137763A3 (pt) 2019-08-21
CA2984637A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
PH12017500834A1 (en) Methods and formulations for treating vascular eye diseases
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MY192226A (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2017001279A (es) Usos y composiciones de la flagelina.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
BR112017023762A2 (pt) formulações de depósito injetáveis
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
EA201690159A1 (ru) Способы и композиции для лечения рака
MX2015016741A (es) Inhibidores de pi3 cinasa delta y gama selectivos duales.
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112017007748A2 (pt) “composição farmacêutica, agente antialérgico, composição alimentar, composição cosmética, uso de um extrato, e, método para prevenir ou tratar uma doença alérgica
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
MX2017013879A (es) Composiciones que comprenden anakinra.
BR112017007095A2 (pt) conjugados e derivados de prostaglandina para tratamento de glaucoma e hipertensão ocular
PH12018502139A1 (en) Phosphaplatin liquid formulations
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]